Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 6/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706647 | 0.82 | CYP19A1 (0.52) | MIFCYP19A1MTNR1AMTNR1BCA1 | |
| SCHEMBL1511852 | 0.80 | BRD4 (0.47) | BRD4NR1H2MTNR1AMTNR1B | |
| SCHEMBL1472801 | 0.77 | CA1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5858918 | 0.76 | KMT2A (0.47) | BRD4KMT2AMTNR1AMTNR1BCA12 | |
| SCHEMBL25887675 | 0.76 | HPGD (0.42) | KMT2AMEN1 | |
| SCHEMBL5860026 | 0.74 | HRH3 (0.41) | MIFHDAC6KMT2AGAAMTNR1A | |
| SCHEMBL2302634 | 0.72 | CYP19A1 (0.51) | MIFHDAC6CYP19A1CA1CA2 | |
| SCHEMBL7297164 | 0.72 | CYP19A1 (0.51) | CYP19A1KMT2AMTNR1AMTNR1BMEN1 | |
| SCHEMBL11459078 | 0.71 | ACHE (0.43) | BRD4KMT2AGAA | |
| SCHEMBL14207086 | 0.71 | HDAC8 (0.43) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109222-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | BRD4 397/4885MIF 1648/4885HDAC6 1224/4885 |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | BRD4 524/4885MIF 3317/4885HDAC6 290/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | BRD4 524/4885MIF 3317/4885HDAC6 290/4885 |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | BRD4 524/4885MIF 3317/4885HDAC6 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.